More Delays on MannKind's Inhaled Insulin: The Pros and Cons

By BNet.com Published at March 18, 2010 Views 237

Biotech company MannKind (MNKD)’s tumultuous quest for approval of its inhaled insulin drug Afrezza has attracted outspoken supporters and detractors — and this week’s complete response letter from the FDA has them at each other’s throats again.

Read the full article at bnet.com

0

Likes

I like this I don't like this

Ask questions, get answers.
Give the community your two cents.
Be the first by adding your comments.